Media Releases
U of T scientists redefine arterial wall inflammation, offering hope for cardiovascular disease treatment
December 7, 2015
TORONTO, ON — Researchers from the University of Toronto have found that a specific cell type plays a key role in maintaining healthy arteries after inflammation. It’s a discovery that could provide treatment options for cardiovascular disease — one of the leading causes of death in Canada.
The researchers found that a specific type of tissue macrophage, a group of white blood cells that defend against infection, are created and operate separately from other macrophages that come from the bone marrow. Unlike bone marrow macrophages, these cells live in the outer layer of the arterial wall, can self-replicate and help to heal the vessel after inflammation.
“We’ve discovered that a group of macrophages are created when the embryo is developing, before the bone marrow is functioning,” said Clinton Robbins, a professor in the Temerty Temerty Faculty of Medicine’s Departments of Laboratory Medicine and Pathobiology and Immunology. “These macrophages can self-replicate and likely regulate the normal function of our arteries. This is a fundamental biological discovery that could play an important role in many cardiovascular diseases.”
The journal Nature Immunology published the results of the study today.
Robbins and his team found that during infection these self-replicating macrophages leave the arterial wall, while macrophages from the bone marrow come in and engulf the bacteria. The team thinks that once inflammation resolves, the self-renewing macrophages return to heal the damaged tissue.
Using a special tagging system, they accurately traced where the macrophages were coming from.
“Previously, we couldn’t identify one macrophage from another because we were limited by technology,” said Robbins, who is also the Peter Munk Chair of Aortic Disease Research in the Toronto General Research Institute at University Health Network. “Now we can see exactly where they’re coming from and where they’re going. Our job now is to get a better understanding of what these different macrophage populations are doing.”
Next, the researchers will study how these resident macrophages interact with their tissue environment and exactly what role they might play in cardiovascular disease. By understanding the relationship between the different cell types, they hope to target inflammation caused by infection or atherosclerosis more effectively.
“We know that while bone marrow macrophages remove bacteria, they can also cause atherosclerosis by entering the arterial wall and multiplying,” said Rickvinder Besla, graduate student and co-lead author. “In the old model, you might try to shut the bone marrow response down, but this leaves the patient immunosuppressed. Our new model suggests we could possibly reduce inflammation by boosting the activity of these self-replicating macrophages.”
Robbins acknowledges that there’s still a lot to learn about the complexity of these macrophages and how they interact with their environment and other cells.
“Arteries are more than tubes that shuttle blood around. They create a complex and dynamic network that reacts to inflammation and disease in different ways. We’re excited to figure out another piece of this puzzle and how we might target cardiovascular disease in the future.”
-30-
ABOUT UNIVERSITY OF TORONTO Temerty Temerty Faculty of Medicine:
The University of Toronto is at the heart of one of the great biomedical research, education and clinical care networks in the world. With nine fully affiliated hospitals and research institutes and 20 community-affiliated hospitals and clinical care sites, the University of Toronto is a research powerhouse that offers unparalleled opportunities for its 6,800 faculty and 7,000-plus students at all levels. Nearly half of Ontario’s medical doctors and 25 per cent of all health and biomedical PhDs in Canada were trained at the University of Toronto, which consistently ranks among the top universities worldwide. www.medicine.utoronto.ca
ABOUT THE PETER MUNK CARDIAC CENTRE
The Peter Munk Cardiac Centre is the premier cardiac centre in Canada. Since it opened in 1997, the Centre has saved and improved the lives of cardiac and vascular patients from around the world. Each year, approximately 55,000 patients receive innovative and compassionate care from multidisciplinary teams in the Peter Munk Cardiac Centre, and the Centre trains more cardiologists, cardiovascular surgeons and vascular surgeons than any other hospital in Canada. The Centre is based at the Toronto General Hospital and the Toronto Western Hospital — members of University Health Network.www.petermunkcardiaccentre.ca
Contact:
Heidi Singer
Media Relations Specialist
Temerty Temerty Faculty of Medicine, University of Toronto
Tel: 416–978-5811
Heidi.Singer@utoronto.ca